Alzheon
ALZHEON, INC.
Alzheon is committed to developing breakthrough medicines for patients suffering from Alzheimer's disease and other neurological disorders.
alzheon.com · Framingham, MA
Funding event
The round itself, as filedInferred stageSeries C+
Sold of offered$78.8M of $500M
Filed2026-09-10
Days since filing23
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-26
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Martin Tolar, M.D., Ph.D.Executive Officer · Director
- Christopher Noel DunnDirector
- Neil W. FlanzraichDirector
- Jordan HellerDirector
- Diane K. Jorkasky, M.D.Director
- Gino SantiniDirector
- Muneer SatterDirector
- Kenneth MaceExecutive Officer
- Susan Abushakra, M.D.Executive Officer
- John Hey, Ph.D.Executive Officer
- Aidan Power, MRCPsychExecutive Officer
- Adem AlbayrakExecutive Officer
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged15.8% sold1.2 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-210
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.